Atox Bio announced new data in an animal model of necrotizing soft tissue infection (NSTI), commonly known as "flesh eating bacteria" demonstrating that administration of a single dose of AB103, given several hours after infection even without any antibiotics, increased survival in animals, and...
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, have announced the publication of results from the Phase II EAGLE clinical trial for BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia, showing that BL-1020...
Onconova Therapeutics, Inc. is presenting new data in five posters and an oral presentation this week summarizing several studies with the company's radioprotectant Ex-RAD® at the 56th Annual Meeting of the Radiation Research Society (RRS), September 25-29 in Maui, Hawaii. In vivo studies show...
Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort...
Yesterday, The Lancet published online the results of the first study comparing the once-daily human GLP-1 analog, Victoza® (liraglutide [rDNA] injection) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in A1C, fasting plasma...